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Abstract 
Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome is a rare disease 
with inflammatory osteoarticular and skin involvement. The pathogenesis of SAPHO 
syndrome remains unclear, but evidence suggests it may be an autoinflammatory disease 
triggered upon exposure to infectious agents in genetically predisposed individuals. 
Induction of the IL-23/Th17 axis as well as neutrophil activation seem to play a key role, and 
therapies targeting these immunological pathways, including TNF-inhibitors, ustekinumab, 
secukinumab and the IL-1 inhibitor anakinra are potential treatment options that need further 
investigation. Here we report a case of a 24-year-old woman suffering from SAPHO 
syndrome who presented at our clinic with palmoplantar pustulosis and sternoclavicular joint 
involvement. Previous treatments with topical steroids and keratolytics combined with 
NSAIDs, intravenous methylprednisolone, methotrexate and salazopyrin had all failed to 
improve symptoms. Therapy with etanercept was not tolerated, and due to a previous 
demyelinating peripheral neuropathy, further treatment with TNF inhibitors was avoided. We 
initiated ustekinumab 45mg, which improved skin manifestations but not joint pain. Dose 
escalation to 90mg initially improved joint pain, but the dose had to be reduced to 45mg 
again due to increased infections. During subsequent 45mg ustekinumab treatment joint 
pain exacerbated so we switched to secukinumab, which improved skin and joint symptoms 
significantly but was associated with a pustular hypersensitivity reaction. Finally, we began 
treatment with apremilast, a pan-cytokine approach, resulting in stabilization of the skin and 
joint symptoms without side effects. To our knowledge, this is the first case report of 
apremilast as a treatment for SAPHO syndrome. 
 
What’s already known about this topic?  
 SAPHO syndrome is a disease of unknown cause but genetically several similarities to auto 
inflammatory diseases have been found. Clinically dermatological and osteoarticular 
manifestations resemble signs of neutrophil activation.  
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 Usual treatments include NSAIDs and corticosteroids but treatment with TNF-alpha or IL-1 
antagonists has also been previously reported. 
 
What does this study add? 
 Given that TNF-alpha, IL-23 and IL-17 together with activated neutrophils are involved in the 
pathogenesis of SAPHO syndrome, blocking of these cytokines are potential strategies in 
treatment-refractory cases. As such, the use of specific cytokine-directed antibodies like 
ustekinumab or secukinumab or pan-cytokine inhibition with apremilast provide further 
therapeutic options in the management of this rare condition.  
 
Introduction  
SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis and osteitis) is a rare disease 
with inflammatory osteoarticular and skin involvement, the most common manifestations 
being palmoplantar pustulosis (PPP, up to 65% of cases) and acne (up to 39% of cases) 
together with inflammation of the axial and sternoclavicular joints 1. 
 
Case report 
A 24-year-old woman suffering from therapy-refractory SAPHO syndrome characterized by 
PPP and mainly sternoclavicular joint involvement was referred to our department. She 
reported intermittent severe pain of the right sternoclavicular joint and both shoulders. An 
MRI showed arthritis and osteitis of the right sternoclavicular joint, discrete arthritis in the 
lumbar vertebral bodies 2 / 5 and the left sacroiliac joint. Dermatological manifestations were 
plantar pustulosis with severe erythema and thick scaling, and palmar pustulosis with mild 
erythema and marked scaling. The maximal palmoplantar psoriasis area and severity index 
(PPPASI) was 31.2 (Figure 1). Additionally, new rapidly progressing nail-alterations 
occurred. CRP was mildly elevated (8.6 mg/L, reference <5) and erythrocyte sedimentation 
rate was normal (14 mm/h). The father of the patient was also diagnosed with SAPHO 
syndrome. Previous topical steroids and keratolytics combined with systemic therapies, 
including NSAIDs, weekly intravenous methylprednisolone, methotrexate and salazopyrin 
had all failed to improve symptoms. Etanercept 50mg weekly was begun but discontinued 
due to severe injection site reactions. Treatment options for the patient at that time were to 
switch to another TNF-alpha inhibitor (TNFi) or ustekinumab, as involvement of the IL-
23/Th17 pathway in SAPHO syndrome has been suggested 2. The latter was favored 
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because of a previously diagnosed demyelinating peripheral neuropathy. TNFi are 
contraindicated in multiple sclerosis and exacerbations or new onset demyelinating diseases 
have been reported during TNFi treatment. 3 The patient was treated with ustekinumab 45 
mg at week 0, 8, 16 and then every 12 weeks. The second injection was delayed compared 
to the standard scheme due to gastrointestinal complaints, but physical examination, 
laboratory workup and gastroscopy remained unsuspicious. During treatment the PPPASI 
score improved dramatically but the treatment had no effect on joint pain, and additional 
treatment with NSAIDs and prednisone showed only little effect. The dose of ustekinumab 
was then increased to 90 mg every 12 weeks with initial significant improvement of joint 
pain. As the patient developed frequent upper airway infections, the dosage had to be 
reduced to 45 mg, which led to recurrence of joint pain and nail alterations. An MRI showed 
persistence of the inflammation of the right sternoclavicular joint, as well as new onset 
inflammation of the left sternoclavicular joint. Ustekinumab was thus discontinued and, as 
the peripheral neuropathy was completely asymptomatic, adalimumab was begun with the 
loading dose of 80 mg followed by 40 mg every other week beginning at week 1. Upon 
treatment with adalimumab, pustulosis and joint pain exacerbated with marked impairment 
of everyday activities. Adalimumab was stopped and secukinumab subsequently initiated 
due to its inhibition of the Th17 pathway and excellent activity in psoriasis and psoriatic 
arthritis 4. Upon treatment with secukinumab, starting with 300 mg weekly over 4 weeks 
followed by 300 mg every 4 weeks, a marked improvement of the PPPASI score was 
observed including improvement of the nail alterations.  
Four months after secukinumab initiation the patient developed a generalized pustular skin 
rash consistent with a drug hypersensitivity reaction. Secukinumab-specific T-cells were 
confirmed by lymphocyte transformation test. Secukinumab was discontinued and 
apremilast, which is approved for psoriasis and psoriatic arthritis, was started (standard 
induction scheme, followed by 30 mg twice daily). During the first four weeks the patient 
experienced common, usually intermittend side effects of apremilast such as headaches, 
diarrhea, nausea and vomiting, which thereafter resolved spontaneously. The clinical 
response of the skin lesions previously achieved with secukinumab was maintained under 
apremilast treatment at 7 months of follow-up, with a PPPASI of 2.4 (Figure 2) and no 
reported joint pain. Change in nail alterations could not be evaluated because of regularly 
applied artificial nails. At present the patient has been treated with apremilast 30 mg twice 
daily for 6 months achieving long lasting disease control without significant side effects. 
When the patient deviates from her treatment plan (apremilast 30mg, twice daily), she 
experiences increased itch with or without pustule formation which abate promptly when she 
returns to her regular dosing schedule. Recently the patient developed one episode of 
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intermittent severe headaches probably caused by the patients’ intake irregularities which 
necessitated a transient reduction in dose (re-induction with one starter pack of apremilast). 
 
Discussion 
Here we present the case of a patient with therapy-refractory SAPHO syndrome successfully treated 
with apremilast. Treatments with biologics such as TNFi or anakinra have been reported in SAPHO 
syndrome, but only a few reported cases with ustekinumab exist and just recently a report with 
secukinumab has been published. Our patient showed disease remission induced by secukinumab 
and maintained through apremilast. As the patient gets flares when deviating from the treatment plan 
with apremilast, we assume that apremilast is suppressing the inflammation sufficiently.  
 
The pathogenesis of SAPHO syndrome remains unclear, however several similarities to 
auto inflammatory diseases have been found. Genetic studies have associated SAPHO 
syndrome with mutations in LPIN2, NOD2 and PSTPIP1 and the HLA-B27, -39 and -61 
alleles have been found more frequently in patients with SAPHO syndrome as compared to 
healthy individuals 6, 7. Recently a multifactorial model where an autoimmune reaction is 
triggered by infectious agents in genetically predisposed individuals has been suggested 5. 
Here pathogens – most importantly Propionibacterium acnes – have been associated with 
SAPHO syndrome in skin biopsies, with reports describing successful treatment with 
antibiotics. In addition, an upregulation of IL-8, IL-17, IL-18, TNF-alpha and IL-1 have been 
shown 8. We did not find evidence of elevated serum cytokines (IL-1beta, IL-6, IL-8, IL-12, 
INF-gamma, TNF-alpha and soluble IL-2 receptor alpha) in our patient, but these 
investigations were done during treatment and no baseline levels were performed. There is 
still debate if chronic recurrent multifocal osteomyelitis (CRMO) belongs to the juvenile 
spectrum of SAPHO syndrome and how the latter can be conclusively differentiated from 
psoriatic arthritis, which rarely shows hyperostosis and osteitis 9.  
Treatment options for SAPHO syndrome include NSAIDs, corticosteroids, antibiotics 
(doxycycline, azithromycin etc.), bisphosphonates, colchicine, methotrexate, sulfasalazine, 
TNFi, anakinra, surgery and recently also ustekinumab and secukinumab 7,10,11. 
Palmoplantar pustular psoriasis with psoriatic arthritis is an important differential diagnosis for SAPHO 
syndrome. Osteitis and arthritis of the sternoclavicular joint rarely occur in psoriatic arthritis but are 
typical features of SAPHO syndrome, which were present in our patient. The cytokine profile of 
SAPHO syndrome was found to be similar to that of psoriasis 
6
, which together with the clinical 
similarities led to the introduction of well-established therapies like TNFi for treatment of SAPHO 
syndrome, with good symptom control in most cases 
12
. Recently also ustekinumab and secukinumab 
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have shown efficacy in SAPHO syndrome with good response on skin manifestations but no 
improvement of joint involvement 
2,10,11
, which is a general issue with most therapies 
7
. In contrast to 
the recently reported cases, our patient’s skin manifestations responded well to ustekinumab and the 
joint pain improved after dose escalation. During secukinumab our patient also achieved good 
disease control with dramatic improvement of the PPPASI and joint pain. 
 
IL-17 is a cytokine produced by Th17 cells, which were shown to be increased in patients suffering 
from SAPHO syndrome 
8
. Since secukinumab had to be discontinued in our patient due to a 
hypersensitivity reaction with positive lymphocyte transformation test, we introduced a treatment with 
apremilast. Apremilast acts via its dialkoxyphenyl ring as a specific phosphodiesterase 4 (PDE-4) 
inhibitor and is non-selective for PDE-4 subtypes. Apremilast enhances intracellular cyclic adenosine 
monophosphate (cAMP) levels through protein kinase A (PKA) phosphorylation and activation, 
resulting in upregulation by cAMP responsive element binding protein (CREB) and down-regulation of 
NF-κB-dependent genes. Consequently, proinflammatory cytokine production of innate and adaptive 
immune cells is downregulated by apremilast. This leads to upregulation of immunomodulatory 
cytokines like IL-10 as well as downregulation of IFN-gamma, TNF-alpha and IL-23. The inhibition of 
PDE-4 skews the balance of cytokines towards an anti-inflammatory state, potentially leading to 
control of the inflammation.  
 
In SAPHO syndrome, diverging responses to different targeted biologicals could reflect the 
involvement of separate proinflammatory pathways including IL-1, IL-17 and TNF-alpha, which may 
suggest further, as yet unrecognized, immunological subtypes of the disease. By treating our patient 
with apremilast, the suppression of pro-inflammatory cytokines such as TNF- and IL-17 
subsequently inhibitis the activation of both, T cells and neutrophils, a “pan-cytokine, multi-cell” 
immunomodulatory approach 
13
. 
 
To our knowledge, this is the first case report of the successful treatment of SAPHO syndrome with 
apremilast; moreover, given the upregulation of the IL-23/IL-17 axis, the effectiveness of 
secukinumab, ustekinumab and apremilast introduce new therapeutic options for SAPHO syndrome 
and warrant further investigation. 
 
Figure legends 
Figure 1 a-c: Palmoplantar manifestation prior to ustekinumab treatment (month 0, PPPASI 
31.2) 
 
Figure 2 a-c: Palmoplantar manifestations during treatment with apremilast (month 23, 
PPPASI 2.4) 
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Figure 3: PPPASI (Palmoplantar Psoriasis Area and Severity Index) and treatments over 
time. Months since beginning of ustekinumab treatment.  
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Figure 2 
 
 
 
Figure 3 
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